Combining Serplulimab with Chemoradiotherapy for High-Risk Postoperative Cervical Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase II clinical trial investigates the effectiveness and safety of Serplulimab, an immunotherapy drug, when combined with chemoradiotherapy as an adjuvant treatment for women with postoperative cervical cancer who have multiple risk factors. The study will enroll female patients aged 18 to 65 who have undergone radical surgery and have at least two adverse pathological factors. Participants will be randomly assigned to receive either the combination treatment or chemoradiotherapy alone. The trial aims to determine if the addition of Serplulimab improves patient outcomes compared to standard treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Voluntarily participate in the clinical study: Fully understand and be informed about the study, and sign the informed consent form (ICF); willing to comply with and capable of completing all trial procedures.
* Female aged ≥18 years and ≤65 years at the time of signing the ICF.
* ECOG PS score of 0 or 1.
* Positive PD-L1 status (CPS ≥1).
* Diagnosed with cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.
* FIGO (International Federation of Gynecology and Obstetrics) stage of IB1, IB2, IIA1, or IIA2, and patients judged by the investigator to benefit from radical surgery and/or adjuvant therapy.
* Have undergone radical hysterectomy (Piver classification) and pelvic lymphadenectomy of type II or III.
* Postoperative pathological examination confirms at least two adverse factors, which may include: Lymph node metastasis; Positive parametrial or positive resection margins; Lymphovascular space invasion; Deep stromal invasion;
* Patients must meet the following hematological, renal, and liver function criteria: Absolute neutrophil count of at least 1.5 × 10⁹/L; Platelet count of at least 100 × 10⁹/L; Total bilirubin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels not exceeding 1.5 times the upper limit of normal; Creatinine levels not exceeding the upper limit of normal.
* Female participants must have a negative serum pregnancy test within 14 days prior to treatment and agree to use effective contraception during the treatment period and for 6 months afterward; breastfeeding is prohibited during treatment.
* Willing and able to comply with the trial and follow-up procedures.

Exclusion Criteria:

* Patients with unresectable residual tumors.
* Histologically confirmed diagnosis of cervical small cell carcinoma (neuroendocrine) or mucinous adenocarcinoma.
* Patients who have previously received pelvic radiotherapy.
* History of other untreated malignant tumors within the past 5 years, except for cured basal cell carcinoma of the skin or carcinoma in situ.
* Presence of any active or known autoimmune disease.
* History of inflammatory/autoimmune diseases requiring steroid treatment, or currently suffering from inflammatory/autoimmune diseases that require steroid treatment.
* Diseases requiring systemic treatment with corticosteroids or other immunosuppressive agents within 14 days prior to randomization.
* History of thromboembolic events (venous or arterial) occurring within 6 months prior to enrollment.
* Poorly controlled clinical symptoms or conditions related to heart disease.

Where it's running

• Tianjin Medical University Cancer Institute & Hospital
  Tianjin, Tianjin Municipality, China Recruiting

Study contacts

• Principal investigator: Maobin Meng, Dr. — Tianjin Medical University Cancer Institute and Hospital
• Study coordinator: Maobin Meng, Dr.
• Email: mmeng@tmu.edu.cn
• Phone: +86 15202231270

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NeoCSR-Omics: CAPOX and Serplulimab Before or After Short-Course RT in Locally Advanced Rectal Cancer

  This trial tests whether giving CAPOX chemotherapy with the PD-1 blocker serplulimab before or after short-course radiotherapy helps people with locally advanced rectal cancer achieve complete clinical or pathological responses.

  Recruiting Phase 2 Chongqing University Cancer Hospital · Chongqing, Chongqing Municipality · NCT07898865

• YL201 plus serplulimab vs the usual chemo combo as first treatment for extensive-stage small cell lung cancer

  This trial tests whether adding YL201 to serplulimab can improve outcomes compared with standard carboplatin and etoposide plus serplulimab in adults with treatment-naïve extensive-stage SCLC.

  Recruiting at 2 sites Phase 3 MediLink Therapeutics (Suzhou) Co., Ltd. · Guangzhou, Guangdong and 1 other locations · NCT07739758

• Moderately hypofractionated radiotherapy after hysterectomy for cervical cancer

  This study tests whether a shorter, moderately intensified radiotherapy course after surgery is safe and effective for patients with cervical cancer.

  Recruiting at 2 sites Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality and 1 other locations · NCT07684508

• Low-dose carboplatin with nab-paclitaxel plus delayed serplulimab as first-line therapy for advanced squamous NSCLC

  This trial tests whether giving a low-dose carboplatin and nab-paclitaxel together, with serplulimab started after a delay, helps people with advanced squamous non-small cell lung cancer who have no known targetable gene mutations.

  Recruiting Phase 2 People's Hospital of Quzhou · Quzhou, Zhejiang · NCT07647094

• HIPEC-primed therapy with serplulimab plus SOX/XELOX for locally advanced gastric cancer

  This study tests a HIPEC-priming approach followed by PD-1 blocker–based chemotherapy to see if it helps people with locally advanced gastric cancer who have not yet spread.

  Recruiting Phase 2 Shanghai Changzheng Hospital · Shanghai · NCT07621484

• Serplulimab plus second-line chemo/targeted therapy for early-relapse colorectal cancer after adjuvant therapy

  This trial tests whether adding serplulimab to standard second-line chemotherapy plus targeted therapy helps people whose colorectal cancer came back early after adjuvant treatment.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07604909

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.